About admin

This author has not yet filled in any details.
So far admin has created 40 blog entries.

VRN02, DYRK1A, Autoimmune diseases

2021-01-27T10:58:58+00:00

[:ko]보로노이의 VRN02 화합물은 DYRK1A를 타겟하는 물질로서, 만성 염증성 질환 치료를 목표로 하고 있습니다. 동물실험 결과, 류마티스 관절염, 루푸스, 건선, 대장염, 아토피성 피부염과 같은 주요 염증 질환에 대한 치료효과를 확인했으며, 타 염증성 질환으로 연구 확대 중입니다. 또한 VRN02 물질은 건선과 아토피 피부염 질환에 있어서 경구용 알약뿐만 아니라, 피부에 바르는 외용제로도 개발할 계획입니다. [:en]VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin. [:]

VRN02, DYRK1A, Autoimmune diseases2021-01-27T10:58:58+00:00

VRN01, LRRK2, Glioblastoma

2020-01-02T02:59:58+00:00

[:ko]보로노이의 VRN01 화합물은 LRRK2를 타겟하는 물질로서, 뇌종양 치료를 목표로 하고 있는 프로그램입니다.
특히, 뇌암 중에서도 가장 악성으로 알려진 교모세포종(GBM: Glioblastoma) 치료에 도전하고 있습니다.[:en]VRN01 program is under development for the treatment of brain tumor, especially GBM (Glioblastoma multiforme) which is known to be the most malignant form of brain tumor, by inhibiting LRRK2 kinase activity.[:]

VRN01, LRRK2, Glioblastoma2020-01-02T02:59:58+00:00

VRN07, EGFR exon 20 insertion. Non-Small Cell Lung Cancer

2021-03-30T14:01:58+00:00

[:ko]보로노이의 VRN07 프로그램은 EGFR Exon 20 insertion을 타겟하는 물질로서, 비소세포폐암 치료를 목표로 하고 있는 프로그램입니다. [:en]Voronoi’s VRN07 program aims to treat NSCLC by targeting EGFR exon 20 insertion. Voronoi aims to also overcome brain metastasis by developing brain-permeable compound. [:]

VRN07, EGFR exon 20 insertion. Non-Small Cell Lung Cancer2021-03-30T14:01:58+00:00

Lilliun

2019-08-17T20:58:32+00:00

Scientific Advisor: Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020). Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016.  She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 300 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology. Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer

Lilliun2019-08-17T20:58:32+00:00

pasi

2019-08-17T20:58:11+00:00

Scientific Advisor: Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston.  He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer.  He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award, a member of the 2010 AACR Team Science Award and the recipient for the 2018 Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship and in 2018 the European Society of Medical Oncology Translational Research Award and the Outstanding Investigator Award (R35) from the National Cancer Institute. Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston.  He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance

pasi2019-08-17T20:58:11+00:00

Lim Jaeyoung / Intellectual Property

2020-10-23T11:11:55+00:00

Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management." Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management."

Lim Jaeyoung / Intellectual Property2020-10-23T11:11:55+00:00

Lee Kyungho

2020-10-23T11:10:52+00:00

(前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab." (前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab."

Lee Kyungho2020-10-23T11:10:52+00:00

Park Junil / Business Development(China and Emerging markets)

2020-01-06T16:46:13+00:00

[:ko]북경대학교를 졸업하고 10여년간 근무한 미래에셋 PEF에서의 경험을 토대로 보로노이의 Globalization과 Value creation을 위한 전략 실행에 노력하고 있습니다.[:en]Before joining Voronoi, Mr. Park dedicated his career to Mirae Asset Private Equity Fund right after his graduation from Pecking University. Based on his 10 years of experience, he is contributing to Voronoi’s strategies for globalization and value creation. [:]

Park Junil / Business Development(China and Emerging markets)2020-01-06T16:46:13+00:00

(Korean) 일터로서의 보로노이

2020-09-03T15:14:32+00:00

Seoul National University, B.S. Fast growth "For Voronoi, it only takes 1.5 years to develop a new drug candidate." For Voronoi, it only takes 1.5 years to develop a new drug candidate while it usually takes 4.5 years in the industry average. The speed is exceptionally high. The reason for this high speed is because we, Voronoi, have many talents and professional experts who majored in molecular modeling, medicinal chemistry, and kinase inhibitor development. Each of them are Dr. Kim, Dr. Choi, and Dr. Gray. They all have previous experience of creating and developing novel small molecule drugs and out-licensing them to global leading pharmaceutical companies. I am proud that I can be also part of this team and the company, learning from them. There are much more to catch up. My job definitely requires fast learning speed. Collaboration "Effective partnership" Voronoi is collaborating with Dana-Farber Cancer Institute, Yonsei University Medical School, Korea Brain Research Institute, National Cancer Center, etc. We also have Dr. Janne of Harvard Medical School as our scientific advisory board for our lung cancer pipeline. We frequently have a discussion with our partners and advisors. Collaboration does not only apply to external partners, but also to internal teams. Voronoi pursue open-minded and respecting working culture and we aim to have effective discussion between teams and divisions. If you can lead effective meetings with bright energy, you will find yourself so fit into our culture. Work & Life balance "Flexible and Efficient" Voronoi pursues flexible and efficient working culture. You don’t need to sit on the chair only to show your presence. Suppose you have personal appointments and want to leave office early. You can always do so if you are done with your work. We give ownership and responsibility to each employee with huge trust. You can find flexible working culture here in Voronoi.

(Korean) 일터로서의 보로노이2020-09-03T15:14:32+00:00

‘Where the possibilities are transitioned to reality.’

2020-01-16T14:43:56+00:00

Yonsei University Health center, Researcher Yonsei University, M.S. Yonsei University Health center Yonsei University, M.S. Work "Hello, I am Donghyuk Seo, and I am in charge of getting IND package ready and done." Q. What do you do in translational research team? ‘Where the possibilities are transitioned to reality.’ If I may introduce translational research team in one sentence, I would like to say it’s a place where the possibilities are transitioned to reality. For many, translational research team may be unfamiliar. It’s a place that is in charge of preclinical research and production of synthetic drugs excluding in vitro field. Our team is divided into DS and DP research parts, which produce synthetic drugs on a large scale, and in vivo efficacy and toxicity research parts. I am in charge of in vivo potency studies, toxicity studies, and clinical trials, which all leads to IND filing. Many types of in vivo potency tests are conducted in animal laboratories within Voronoi. However, there are some of the studies that needs to be done by CROs including immunological disease model for determining the anti-inflammatory effects, or GLP Toxicology studies to determine whether a drug is toxic. These studies are led by translational research team so that the whole IND package is ready and done. To applicants, “Pay no mind to fear, be strong!” Q. What are the requirements for your work? There are a lot of requirements including scientific background. However, other than scientific knowledge, you would need to have certain level of business communication skillsets as you will work dynamically with overseas CROs. Q. Any last advice? The feeling that pops up on my mind when I think back of the time I was looking for a job is “fear”, a doubt whether I can do it well or not. Don’t be afraid, be strong and bold with confidence that you can achieve, then I assure you that you will end up with a very sweet and mysterious result.

‘Where the possibilities are transitioned to reality.’2020-01-16T14:43:56+00:00